Diabetes

Prioritizing SDOH for Patients Living with Chronic Diseases: Compassion, Coordination and Community

As the U.S. healthcare system works to focus on the move to preventive, personalized care for patients, it’s time to turn the tide on diabetes by addressing the three Cs of chronic disease care: compassion, coordination, and community.

By Javier La Fontaine and Gary Rothenberg

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Consumer / Employer, Health Tech

Amazon’s Automatic Coupons for Diabetes Products While “Incremental” Will Still Be a “Gamechanger,” Experts Say

Amazon Pharmacy announced Tuesday that it is launching automatic coupons for more than 15 insulin and diabetes care brands. The move, while incremental, solves a major pain point for consumers with diabetes, as many struggle to afford insulin products.

By Marissa Plescia

Devices & Diagnostics

Recent Abbott Snafu Shines Spotlight on Social Media’s Role in Public Health Crisis Response

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

By Katie Adams

Health Tech

Oura Will Now Share Its Sleep Scores With CGM Providers

Oura — a company selling a ring that tracks peoples’ biometrics — announced new partnerships with three providers of continuous glucose monitors: January, Supersapiens and Veri. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users’ glucose levels and overall health.

By Katie Adams

Devices & Diagnostics

Meet the Company Building the First-Ever Noninvasive Blood Glucose Monitoring Device

Know Labs recently unveiled the prototype for its non-invasive, portable glucose monitoring device. The device incorporates the company's proprietary body-radio frequency identification (Bio-RFID) technology — meaning its sensors deploy radio waves that travel through the skin to find and measure molecular signatures in the blood.

By Katie Adams

MedCity Influencers

Is It Possible To Provide Equitable Nutritional Care for Diabetes and Obesity?

With obesity, diabetes, and heart disease rapidly growing among communities of color, we need to do everything we can to help people sustain healthy eating habits. It’ll take more nuance than a Westernized one-size-fits-all diet.

By Gretchen Zimmermann

Devices & Diagnostics

Medtronic Gains FDA Approval for Newest Insulin Pump

Medtronic recently received FDA approval for its MiniMed 780G system, which is an insulin pump that automatically adjusts and corrects type 1 diabetes patients’ glucose levels every five minutes. The news comes two years after Medtronic submitted the system for FDA approval and three years after the company began selling the product in Europe.

By Katie Adams

BioPharma, Pharma

Eli Lilly Unloads Emergency Nasal Spray Diabetes Drug for $500M Up Front

Eli Lilly is selling to Amphastar Pharmaceuticals global rights to Baqsimi, an emergency treatment for severe hypoglycemia in diabetes patients. The deal come as Lilly turns its focus to novel medicines for diabetes and other indications.

By Frank Vinluan

Health Tech, Payers

MedCity Pivot: Blue Shield of California CEO Says Value of HealthTech Has Been Mixed So Far

Paul Markovich believes in the value of health tech in managing both chronic diseases and in general health and wellness. In this episode, he talks about the company's Wellvolution platform and the digital tools that are offered there to members, now even to those on Medicaid.

By Arundhati Parmar

Health Services

Maximize Revenue and Patient Care with Strategic Weight Loss Management

We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.

By Build My Health and MedCity News

BioPharma, Pharma

Novo Nordisk Follows Eli Lilly’s Lead, Lowering Insulin Prices up to 75%

Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.

By Frank Vinluan

BioPharma, Pharma

Eli Lilly’s Insulin: Cheaper for Patients Without Much Financial Hit to the Firm

Eli Lilly is slashing prices for its insulin products and capping a patient’s monthly out-of-pocket costs at $35. But a financial analyst notes that the company can afford to cut prices on older medicines like insulin because the strategy will help it maintain pricing power for innovative new drugs.

By Frank Vinluan

Health Tech, Payers

Blue Shield of California Adds Virta Health to Network for Diabetes Care

Virta is available this month to all Blue Shield of California members enrolled in preferred provider organization plans for individual and family, fully insured, self funded and Medicare Advantage. The payer has been working with Virta since 2019 when the digital health company joined Blue Shield of California’s Wellvolution, a platform of digital lifestyle apps.

By Marissa Plescia

BioPharma, Pharma

Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologics

Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.

By Frank Vinluan

Health Tech, Consumer / Employer

With Livongo, did Zane Burke sell a lemon to Teladoc’s Jason Gorevic?

Was Livongo a good business? As Burke, now CEO of Quantum Health, touts its strength to investors ahead of a potential IPO, should the Livongo-Teladoc history give them pause?

By Arundhati Parmar